Kyowa Kirin Full Year 2024 Earnings: EPS Misses Expectations

Kyowa Kirin (TSE:4151) Full Year 2024 Results

Key Financial Results

• Revenue: JP¥495.6b (up 12% from FY 2023).
• Net income: JP¥59.9b (down 26% from FY 2023).
• Profit margin: 12% (down from 18% in FY 2023). The decrease in margin was driven by higher expenses.
• EPS: JP¥113 (down from JP¥151 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kyowa Kirin EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 13%.

Looking ahead, revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are down 8.8% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Kyowa Kirin has 2 warning signs we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.